CLSA Capital Partners

CLSA Capital Partners, founded in 1999, serves as the alternative asset management arm of CLSA, a prominent independent brokerage and investment group based in Hong Kong. The firm specializes in private equity, private credit, and private real estate strategies, focusing on investments in diverse sectors. Notably, it manages funds such as the buyout fund in collaboration with Shanghai Guosheng Fund, which targets investments in green technology, commercial products, and financial services within China. Additionally, CLSA Capital Partners engages in various investment opportunities in Japan through other funds, reinforcing its commitment to the Asia-Pacific region.

Hidetsugu Agata

Director

Alvin Ho

Managing Director and Head of Growth and Expansion

Derek Hung

Managing Director and Head of Transaction Management

Peter Min

Managing Director and Head of Pacific Transportation

Shunji Naka

Managing Director

Gregory Park

Managing Director, Head of Lending Ark and Chairman of the Investment Committee

Carol Park

Managing Director and Member of the Investment Committee

John Patter

Managing Director

Naotsugu Saito

Managing Director

Miranda Tang

Director and Managing Director of ARIA Funds

Vaibhav Totla

Managing Director

Anthony Wilkinson

Principal and Head of Research

Past deals in Taiwan

ACT Genomics

Series C in 2018
ACT Genomics Co., Ltd. is a cancer molecular information service company based in Taipei City, Taiwan, with additional locations in Hong Kong, Singapore, and Japan. Established in 2014, the company specializes in transforming cancer genomic information into precision diagnostics and personalized treatment options. Through advanced technologies, including next-generation sequencing and bioinformatics tools, ACT Genomics offers comprehensive tumor profiling that identifies specific genetic alterations driving cancer pathogenesis and treatment responses. Their services include integrated genomic analysis, clinical reporting on genomic alterations and therapeutic implications, and profiling of cancer-related genes. Additionally, ACT Genomics assists in predicting responses to immunotherapy and monitoring tumor burden through circulating tumor DNA detection. The company's innovative approach aims to enhance the effectiveness of oncology treatment decisions, making personalized medicine more accessible and impactful.

Fulltech Fiber Glass

Private Equity Round in 2008
Fulltech Fiber Glass Corp. produces and sells fiber glass yarn and fabrics in Taiwan. It offers electronic grade fiber glass yarn for use in the manufacture of fiber glass fabric, printed circuit boards, desktop and laptop computers, cellular phones, PDAs, and projection cloths, as well as industrial grade fiber glass yarn for use in the manufacture of insulation tubes. The company was founded in 1999 and is based in Taipei, Taiwan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.